VOYAGER THERAPEUTICS INC (VYGR) Stock Income Statement
NASDAQ:VYGR - Nasdaq - US92915B1061 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 66.96M | 80.00M | 250.01M | 40.90M | 37.40M | |||
| Operating Expenses | 165.96M | 160.49M | 127.99M | 91.70M | 111.00M | |||
| Research and Development | 129.00M | 124.57M | 92.17M | 60.80M | 73.80M | |||
| Selling, General, and Administrative Expenses | 36.95M | 35.92M | 35.82M | 31.00M | 37.20M | |||
| Operating Income | -99.00M | -80.49M | 122.01M | -50.80M | -73.60M | |||
| Interest Income/Expense | 16.75M | 18.33M | 11.72M | 1.80M | -400.00K | |||
| Other Income/Expense | 1.04M | 622.00K | 3.00K | 2.70M | 2.80M | |||
| Non Recurring Items | N/A | -2.80M | N/A | N/A | N/A | |||
| Income Before Taxes | -84.00M | -64.34M | 133.74M | -46.40M | -71.20M | |||
| Income Tax | 688.00K | 665.00K | 1.41M | 0.00 | N/A | |||
| Net Income | -84.69M | -65.00M | 132.33M | -46.40M | -71.20M | |||
| EBITDA | -94.45M | -75.76M | 126.45M | -44.61M | -68.43M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.46 | -1.13 | 2.97 | -1.21 | -1.89 | |||
| Non GAAP EPS | -1.46 | -1.13 | 3.09 | -1.22 | -1.90 | |||
| Statistics | ||||||||
| Profit Margin | -126.49% | -81.25% | 52.93% | -113.45% | -190.37% | |||
| Operating Profit Margin | -147.85% | -100.61% | 48.80% | -124.21% | -196.79% | |||
All data in USD